(Source: Eisai Co Ltd) Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, 'Eisai') announced today the initiation of a Phase II clinical study of its internally-discovered oral dual orexin receptor antagonist lemborexant (development code: E2006) in patients with Irregular Sleep-Wake Rhythm Disorder (ISWRD) and mild to moderate Alzheimer's disease (AD) dementia. Lemborexant is being jointly developed by Eisai and Purdue Pharma L.P. (Headquarters: Connecticut, United States, President and CEO: Mark Timney). ISWRD is a type of circadian rhythm sleep disorder where the pattern of sleep and wakefulness that repeats itself over a 24 hour period in healthy individuals is broken down, and...
↧